Classically, the D-2 receptors formed the Gore of the dopamine hypothe
sis for schizophrenia. Recently, the dopamine D-4 receptors have recei
ved particular attention in this context. This is due to the atypical
antipsychotic, clozapine, which is effective in treating refractory sc
hizophrenics without the side-effect profile of typical neuroleptics,
and displays a ten-fold higher affinity for D-4 compared to D-2 or D-3
receptors. Following various reports presenting the interest of D-4 r
eceptors in treating schizophrenia, multiple chemical developments wer
e made. During the last five years, various structures were described
with a high selectivity for D-4 receptor subtype. Currently, although
the first clinical report was very disappointing, the observation whic
h support the idea that D-4 might serve as a target for clozapine have
significantly modified and extended the understanding of mechanism un
derlying atypical antipsychotic treatment of schizophrenia.